KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2025)

Historic Gross Margin for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to 93.16%.

  • Rigel Pharmaceuticals' Gross Margin rose 76700.0% to 93.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.1%, marking a year-over-year increase of 36700.0%. This contributed to the annual value of 89.6% for FY2024, which is 43200.0% down from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Gross Margin is 93.16%, which was up 76700.0% from 95.57% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Gross Margin registered a high of 99.61% during Q1 2021, and its lowest value of 85.49% during Q3 2024.
  • In the last 5 years, Rigel Pharmaceuticals' Gross Margin had a median value of 96.0% in 2023 and averaged 95.19%.
  • In the last 5 years, Rigel Pharmaceuticals' Gross Margin tumbled by -100000bps in 2024 and then skyrocketed by 76700bps in 2025.
  • Rigel Pharmaceuticals' Gross Margin (Quarter) stood at 97.61% in 2021, then grew by 2bps to 99.33% in 2022, then fell by -10bps to 89.41% in 2023, then grew by 1bps to 89.95% in 2024, then increased by 4bps to 93.16% in 2025.
  • Its Gross Margin was 93.16% in Q3 2025, compared to 95.57% in Q2 2025 and 91.73% in Q1 2025.